177 related articles for article (PubMed ID: 31531696)
1. Induction of tumor-specific CD8
Tomita Y; Watanabe E; Shimizu M; Negishi Y; Kondo Y; Takahashi H
Cancer Immunol Immunother; 2019 Oct; 68(10):1605-1619. PubMed ID: 31531696
[TBL] [Abstract][Full Text] [Related]
2. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
[TBL] [Abstract][Full Text] [Related]
4. Late dendritic cells are still able to evoke a potent alloreactive CTL response.
Repnik U; Bergant M; Wraber B; Jeras M
Immunobiology; 2008; 213(1):51-64. PubMed ID: 18207027
[TBL] [Abstract][Full Text] [Related]
5. Recombinant mammaglobin A adenovirus-infected dendritic cells induce mammaglobin A-specific CD8+ cytotoxic T lymphocytes against breast cancer cells in vitro.
Cui H; Zhang W; Hu W; Liu K; Wang T; Ma N; Liu X; Liu Y; Jiang Y
PLoS One; 2013; 8(5):e63055. PubMed ID: 23650543
[TBL] [Abstract][Full Text] [Related]
6. Induction of
Shang S; Kats D; Cao L; Morgun E; Velluto D; He Y; Xu Q; Wang CR; Scott EA
Front Immunol; 2018; 9():2709. PubMed ID: 30538700
[TBL] [Abstract][Full Text] [Related]
7. A low, non-toxic dose of paclitaxel can prevent dendritic cell-precursors from becoming tolerogenic dendritic cells with impaired functions.
Matsuhashi T; Shimizu M; Negishi Y; Takeshita T; Takahashi H
Biomed Res; 2014; 35(6):369-80. PubMed ID: 25743343
[TBL] [Abstract][Full Text] [Related]
8. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
Zhang X; Kedl RM; Xiang J
Biochem Biophys Res Commun; 2009 Feb; 379(4):954-8. PubMed ID: 19135981
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.
Koido S; Hara E; Homma S; Mitsunaga M; Takahara A; Nagasaki E; Kawahara H; Watanabe M; Toyama Y; Yanagisawa S; Kobayashi S; Yanaga K; Fujise K; Gong J; Tajiri H
J Immunol; 2007 Oct; 179(7):4874-83. PubMed ID: 17878387
[TBL] [Abstract][Full Text] [Related]
10. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
11. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice.
Moulton RA; Mashruwala MA; Smith AK; Lindsey DR; Wetsel RA; Haviland DL; Hunter RL; Jagannath C
J Leukoc Biol; 2007 Oct; 82(4):956-67. PubMed ID: 17675563
[TBL] [Abstract][Full Text] [Related]
12. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo.
Ishii K; Shimizu M; Kogo H; Negishi Y; Tamura H; Morita R; Takahashi H
Immunobiology; 2020 Jan; 225(1):151860. PubMed ID: 31812347
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
14. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
15. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.
Jongbloed SL; Kassianos AJ; McDonald KJ; Clark GJ; Ju X; Angel CE; Chen CJ; Dunbar PR; Wadley RB; Jeet V; Vulink AJ; Hart DN; Radford KJ
J Exp Med; 2010 Jun; 207(6):1247-60. PubMed ID: 20479116
[TBL] [Abstract][Full Text] [Related]
16. A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer.
Hong CY; Kim SY; Lee HJ; Lee SE; Lim SC; Rhee JH; Lee JJ
J Immunother; 2014 Jan; 37(1):16-25. PubMed ID: 24316552
[TBL] [Abstract][Full Text] [Related]
17. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.
Fossum E; Grødeland G; Terhorst D; Tveita AA; Vikse E; Mjaaland S; Henri S; Malissen B; Bogen B
Eur J Immunol; 2015 Feb; 45(2):624-35. PubMed ID: 25410055
[TBL] [Abstract][Full Text] [Related]
18. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
[TBL] [Abstract][Full Text] [Related]
20. Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Transl Oncol; 2019 May; 21(5):636-645. PubMed ID: 30368725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
